X0508 4 2023-07-18 0 0001601830 RECURSION PHARMACEUTICALS, INC. RXRX 0001855980 Secora Michael C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET SALT LAKE CITY UT 84101 0 1 0 0 Chief Financial Officer 1 Class A Common Stock 2023-07-18 4 M 0 37500 2.22 A 855413 D Class A Common Stock 2023-07-18 4 S 0 24500 13.6236 D 830913 D Class A Common Stock 2023-07-18 4 S 0 500 14.048 D 830413 D Class A Common Stock 2023-07-19 4 M 0 37500 2.22 A 867913 D Class A Common Stock 2023-07-19 4 S 0 1991 14.3626 D 865922 D Class A Common Stock 2023-07-19 4 S 0 13150 15.3626 D 852772 D Class A Common Stock 2023-07-19 4 S 0 9859 15.999 D 842913 D Stock Option (Right to Buy) 2.22 2023-07-18 4 M 0 37500 0.00 D 2030-03-03 Class A Common Stock 37500 707813 D Stock Option (Right to Buy) 2.22 2023-07-19 4 M 0 37500 0.00 D 2030-03-03 Class A Common Stock 37500 670313 D Stock Option (Right to Buy) 2.22 2030-03-03 Class A Common Stock 0 1500000 D Stock Option (Right to Buy) 11.14 2032-02-04 Class A Common Stock 0 116684 D Stock Option (Right to Buy) 11.14 2022-02-04 2032-02-04 Class A Common Stock 0 3914 D Stock Option (Right to Buy) 8.55 2033-02-01 Class A Common Stock 0 404857 D Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023. This transaction was executed in multiple trades at prices ranging from $13.00 to $13.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $14.01 to $14.09. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $13.78 to $14.76. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $14.78 to $15.77. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $15.78 to $16.66. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. /s/ Jonathan Golightly, attorney-in-fact 2023-07-19